Pfizer
Trade Pfizer 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About PFE
Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases.
PFE Key Statistics
Stock Snapshot
As of today, Pfizer(PFE) shares are valued at $25.72. The company's market cap stands at 146.07B, with a P/E ratio of 14.99 and a dividend yield of 6.7%.
On 2025-11-27, Pfizer(PFE) stock moved within a range of $25.58 to $25.81. With shares now at $25.72, the stock is trading +0.5% above its intraday low and -0.3% below the session's peak.
Trading activity shows a volume of 33.46M, compared to an average daily volume of 69.69M.
Over the past 52 weeks, Pfizer(PFE) stock has traded between a high of $27.69 and a low of $20.92.
Over the past 52 weeks, Pfizer(PFE) stock has traded between a high of $27.69 and a low of $20.92.
PFE News
Novo Nordisk NVO and Pfizer PFE are pharmaceutical giants based in Denmark and the United States, respectively, with strong leadership positions in distinct the...
Wondering if Pfizer’s current share price truly reflects its value? You’re not alone, and now might be the perfect time to dig into what the numbers are telling...
Key Points Pfizer and Johnson & Johnson are healthcare leaders and faithful dividend payers. Home Depot is facing a difficult operating environment, but its c...
Analyst ratings
56%
of 27 ratingsMore PFE News
Valneva SE (NASDAQ:VALN) shared final immunogenicity and safety data on Wednesday from the Phase 2 study, VLA15-221, of the Lyme disease vaccine candidate, VLA1...
The weight loss drug market may approach almost $100 billion by the end of the decade. The words "Ozempic" and "Wegovy" almost have become household names as t...
Pfizer is trying to prove it can grow again. After a year of cost-cutting and strategic deals, the drugmaker’s $10 billion purchase of Metsera is just one part...
Monday’s total option volume of 62.3 million contracts resulted in net open interest growth of 9.92 million calls and 6.07 million puts. NVIDIA (NVDA), Tesla (T...
This big pharma stock should be even more appealing to investors amid market turbulence. You may have noticed that the markets are exceptionally volatile at th...
Pfizer and Astellas Pharma recently announced that the FDA approved PADCEV, combined with Keytruda, as a perioperative treatment for adults with muscle-invasive...
Guggenheim raised the firm’s price target on Pfizer (PFE) to $35 from $33 and keeps a Buy rating on the shares. Pfizer’s acquisition of Metsera (MTSR) is “a wis...